Diffusion Pharmaceuticals Inc. (DFFN), a Healthcare Biotechnology organization, saw its stock exchange 32,209,613 shares, a lower amount when compared to its 10-day trading volume of 1.75M. Diffusion Pharmaceuticals Inc. (DFFN) stock traded at $0.5019, up 0.0619 cents or +14.07% on the day. Based on this we can see some traders are either waiting on the sidelines to get involved or perhaps some are taking profits. and the EBITDA is $-11.45M.
Diffusion Pharmaceuticals Inc. (DFFN) Technical Figures:
The average 10-day trading volume of Diffusion Pharmaceuticals Inc. (DFFN) is 1.75M compared to 3.97M over the last 3 months which indicates a lower amount in trading activity. Right now, Diffusion Pharmaceuticals Inc. (DFFN) has a 50-day moving average of $0.3703 and a 200-day moving average of $0.5287. These moving averages are popular technical figures that investors use to analyze price trends of Diffusion Pharmaceuticals Inc. (DFFN). Approximately 0.74% of the shares of the company are sold short from investors betting the stock might trade lower. The beta value of Diffusion Pharmaceuticals Inc. (DFFN) stock is 0.43, indicating its 14.52% to 17.30% more volatile than the overall global market. Technically, DFFN’s short term support levels are around $0.38, $0.36 and $0.33 on the downside. DFFNs short term resistance levels are $0.85, $0.61 and $0.54 on the upside.
Based on technical analysis, DFFN has short term rating of Bullish (0.34), Intermediate rating of Bullish (0.46) and the long-term rating of Neutral (0.11) giving it an overall rating of Bullish (0.30). DFFN is trading 137.87% off its 52 week low at $0.21 and -92.27% off its 52 week high of $6.49. Performance wise, DFFN stock has recently shown investors 14.33% a surge in a week, 72.83% a surge in a month and 13.04% a surge in the past quarter. More importantly, Diffusion Pharmaceuticals Inc. (DFFN) has shown a return of 8.94% since the start of the year.
Diffusion Pharmaceuticals Inc. (DFFN) Key Research:
Diffusion Pharmaceuticals Inc. (DFFN) is a micro-cap company with a market cap value of $17.368M. DFFN insiders hold roughly 0.26% of the shares. On Mar-21-18 H.C. Wainwright Initiated DFFN as Buy at $1.25.
There are currently 34.51M shares in the float and 35.58M shares outstanding. There are 0.74% shares short in DFFNs float. The industry rank for Diffusion Pharmaceuticals Inc. (DFFN) is 10 out of 252 ranking it at the Top 4% .
Diffusion Pharmaceuticals Inc. (DFFN) Fundamental Evaluation:
DFFN last 2 years revenues have increased from $0 to $0 showing an uptrend. Wall Street expects Diffusion Pharmaceuticals Inc. (DFFN) to report an EPS next Qtr loss of -0.09 and a profit of 30.60% next year. The growth rate on DFFN this year is -73.30 compared to an industry 7.90. DFFNs next year’s growth rate is 2.13 compared to an industry 5.50. The book value per share (mrq) is 1.36 and cash per share (mrq) is 0.40. Giving them a price/book (mrq) of 0.73 compared to an industry of 3.24 DFFN fundamental ratios shows an EPS growth vs. previous year -0.47 and EPS growth vs. previous quarter -0.09.
About Diffusion Pharmaceuticals Inc. (DFFN):
Diffusion Pharmaceuticals Inc. is a biotechnology company. Its product pipeline includes Trans Sodium Crocetinate, Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. The Company is focused on cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant solid tumors. Diffusion Pharmaceuticals Inc., formerly known as RestorGenex Corporation, is based in Charlottesville, United States.